Qualitative Concept
Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M
genentech, GenEdit, Gene Modification, Obstetric Delivery
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy